REGULATORY
MOF Panel Pushes for Full Drug Price Revision in FY2027: Budget Proposal
By Kohei Hori November 20, 2026
Japan’s Fiscal System Council on November 20 submitted its budget recommendation for FY2027 to Finance Minister Satsuki Katayama, renewing its call for a full-scale off-year drug price revision next April and a more selective approach…

LATEST

November 20, 2026
The decision to expand Japan’s cost-effectiveness assessment (CEA) system is “deeply disappointing” and risks eroding confidence in the government’s growth strategy, a US pharma industry leader said, pressing for drastic drug pricing reforms to counter…
November 20, 2026
A Japanese health ministry panel on November 19 discussed how to prioritize vaccines and antibody products being considered for inclusion in the national immunization program (NIP) from FY2027, with many members calling for mumps vaccinations…
November 20, 2026
Nipro aims to expand the number of medical facilities administering its stem cell therapy Stemirac from the current 17 to 50-60, making the treatment available in all 47 prefectures following its landmark full approval in…
By Shunsuke Tani

Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…

Japan’s health ministry on November 16 approved AbbVie’s glabellar lines drug Boey (trenibotulinumtoxinE), along with a slate of label expansions…

By Shinya Sato

Japan’s push to expand biosimilar use is running into a troubling supply problem. All seven ingredients that made their biosimilar…

By Kohei Hori

A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…

By Hayate Horiguchi

A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…

Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…

Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

NEWS CATEGORY

REGULATORY

BUSINESS

ORGANIZATION

ACADEMIA